Dr Danijela Tatovic

2024

• Tatovic, D. et al. 2024. Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial. Nature Medicine 30, pp. 2657-2666. (10.1038/s41591-024-03115-2)

2023

• Hanna, S. J. et al. 2023. Single-cell RNAseq identifies clonally expanded antigen-specific T-cells following intradermal injection of gold nanoparticles loaded with diabetes autoantigen in humans. Frontiers in Immunology 14, article number: 1276255. (10.3389/fimmu.2023.1276255)
• Tatovic, D., Narendran, P. and Dayan, C. M. 2023. A perspective on treating type 1 diabetes mellitus before insulin is needed. Nature Reviews Endocrinology 19, pp. 361-370. (10.1038/s41574-023-00816-5)

2022

• Tatovic, D. et al. 2022. Diagnosing Type 1 diabetes in adults: Guidance from the UK T1D Immunotherapy consortium. Diabetic Medicine 39(7), article number: e14862. (10.1111/dme.14862)
• Tatovic, D. et al. 2022. Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in Type 1 diabetes. Immunotherapy Advances 2(1), article number: ltac002. (10.1093/immadv/ltac002)

2021

• Gregory, J. W. et al. 2021. Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol. BMJ Open 11(10), article number: e049595. (10.1136/bmjopen-2021-049595)
• Hanna, S. J., Tatovic, D., Thayer, T. C. and Dayan, C. M. 2021. Insights from single cell RNA sequencing Into the immunology of type 1 diabetes- cell phenotypes and antigen specificity. Frontiers in Immunology 12, article number: 751701. (10.3389/fimmu.2021.751701)
• Tatovic, D. and Dayan, C. M. 2021. Replacing insulin with immunotherapy: Time for a paradigm change in Type 1 diabetes. Diabetic Medicine 38, article number: e14696. (10.1111/dme.14696)

2019

• Yang, J. H. M. et al. 2019. Phenotypic analysis of human lymph nodes in subjects with new-onset type 1 diabetes and healthy individuals by flow cytometry. Frontiers in Immunology 10, pp. -., article number: 2547. (10.3389/fimmu.2019.02547)
• Dayan, C. M., Korah, M., Tatovic, D., Bundy, B. N. and Herold, K. C. 2019. Changing the landscape for type 1 diabetes: the first step to prevention. Lancet 394(10205), pp. 1286-1296. (10.1016/S0140-6736(19)32127-0)
• Dul, M. et al. 2019. Conjugation of a peptide autoantigen to gold nanoparticles for intradermally administered antigen specific immunotherapy. International Journal of Pharmaceutics 562, pp. 303-312. (10.1016/j.ijpharm.2019.03.041)

2016

• Tatovic, D., Luzio, S., Dunseath, G., Liu, Y., Alhadj Ali, M., Peakman, M. and Dayan, C. M. 2016. Stimulated urine C-peptide creatinine ratio vs serum C-peptide level for monitoring of β-cell function in the first year after diagnosis of Type 1 diabetes. Diabetic Medicine 33(11), pp. 1564-1568. (10.1111/dme.13186)
• Zhao, X. et al. 2016. Microneedle delivery of autoantigen for immunotherapy in type 1 diabetes. Journal of Controlled Release 223, pp. 178-187. (10.1016/j.jconrel.2015.12.040)

2015

• Alhadj Ali, M. et al. 2015. Topical steroid therapy induces pro-tolerogenic changes in Langerhans cells in human skin. Immunology 146(3), pp. 411-422. (10.1111/imm.12518)
• Tatovic, D., Young, P., Kochba, E., Levin, Y., Wong, F. S. and Dayan, C. M. 2015. Fine-needle aspiration biopsy of the lymph node: a novel tool for the monitoring of immune responses after skin antigen delivery. Journal of Immunology 195(1), pp. 386-392. (10.4049/jimmunol.1500364)
• Tatovic, D. 2015. Optimising the delivery and monitoring of peptide immunotherapythe delivery and monitoring of peptide immunotherapy for Type 1 diabetes. PhD Thesis, Cardiff University.

2013

• Tatovic, D., Pearton, M., Birchall, J. C., Wong, S. and Dayan, C. M. 2013. Topical steroid has the potential of modulating skin dendritic cells to tolerogenic antigen presenting cells in human organ skin bath culture [Abstract]. Diabetic Medicine 30(s1), pp. 53-53. (10.1111/dme.12091_1)